Management algorithm for genotype 1 hepatitis C virus by Kim, Arthur Y.
 
Management algorithm for genotype 1 hepatitis C virus
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Kim, Arthur Y. 2013. “Management algorithm for genotype 1
hepatitis C virus.” F1000Prime Reports 5 (1): 24.
doi:10.12703/P5-24. http://dx.doi.org/10.12703/P5-24.
Published Version doi:10.12703/P5-24
Accessed February 19, 2015 2:04:56 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717678
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAManagement algorithm for genotype 1 hepatitis C virus
Arthur Y. Kim
Address: Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Email: akim1@partners.org
F1000Prime Reports 2013, 5:24 (doi:10.12703/P5-24)
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. You may not use this work for commercial purposes.
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/5/24
Abstract
Hepatitis C virus (HCV) infection is the most common etiology of chronic liver disease in Western
countries. Morbidity and mortality due to HCV-related end-stage liver disease are increasing, just as
novel therapeutics arrive with the promise of better cure rates that prevent these complications.
However, substantial barriers to successful application of these novel treatments remain, including
the lack of providers with sufficient knowledge to address this epidemic. To address these deficits,
this article aims to provide a general framework with algorithms to guide initial management decisions
for HCV genotype 1 infection, the most commonly found genotype, based on therapies approved as
of 2013.
Introduction
Hepatitis C virus (HCV) usually establishes a chronic viral
infection that infects 1-2% of the United States populat-
ionorabout3-4millionpeople[1].HCVhasemergedasa
leading killer of adults who were predominantly infec-
ted in the 1970s and 1980s, but decades later suffer from
complications due to cirrhosis and end-stage liver disease.
Mortality attributable to HCV currently exceeds that of
humanimmunodeficiencyvirus(HIV)intheUnitedStates
[2]. Cure of HCV, termed a sustained virologic response
(SVR), is associated with a substantial decline in liver-
related morbidity and mortality [3]. From 2002 to 2011,
the standard of care for antiviral treatment was a com-
bination of injectable pegylated interferon (PegIFN) and
oral ribavirin, a treatment regimen only effective in ~50%
of individuals [4]. Treatment uptake has been low for
a variety of reasons, including lowered efficacy against
genotype1,themostcommonlyfoundHCVintheUnited
States, Europe, and Japan, and significant side effects
associated with treatment.
In 2011, two novel agents that potently inhibit the viral
protease, boceprevir and telaprevir, were approved for use
against HCV genotype 1 infections in the United States
(see Table 1). One of these oral medications may be
added to the standard regimen as part of a “triple therapy”
regimen and increase response rates substantially [5]. For
the patient naïve to therapies, response rates improved
from ~40% for PegIFN/ribavirin to 65-70% when one
adds either of these protease inhibitors to the regimen
[6,7].However,theseagentsaddsubstantialcomplexityto
management due to pill burden (multiple pills consumed
every 7-9 hours), drug-drug interactions, and additive side
effects.
Future regimens active against genotype 1 HCV are on the
horizon, promising both improved efficacy and tolera-
bility [8,9]. A significant proportion of candidates for
treatment in 2013 may elect to wait for these novel
therapies, due in the coming years. Therefore, a first step is
toprovideguidelinesforselectingtreatmentcandidatesfor
current versus future therapies in the context of a rapidly
changing field. Then, if treatment is recommended,
management algorithms are needed for providers to treat
with “triple therapy.”
The focus of this article is the management of genotype 1
HCV infection in those naïve to interferon-based thera-
pies. Guidelines are available for non-genotype 1 HCV
infection and those with prior treatment experience
[4,10,11].Whilealgorithmsandchecklistsmaybehelpful,
treatment decisions are ultimately individualized.
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Theprimarygoalofinterferon-basedtherapiesagainstHCV
is achievement of SVR, defined as an undetectable viral
load in the plasma weeks after therapy. The measurement
traditionally occurred at least 24 weeks after cessation of
therapy, but recently it has been appreciated that undetect-
able virus measured at 12 weeks after cessation correlates
extremely well with the 24-week measurement [12], which
inturnisassociatedwithadurablecure[13].Adurablecure
achieves a substantial reduction in liver-related morbi-
dity and mortality [3,14,15]. Other objectives of antiviral
therapy may be to treat conditions and symptoms that
may rarely occur in relation to chronic infection (such as
cryoglobulinemia), to reduce further transmission risk, to
facilitate the application of other hepatotoxic therapies
[16,17] and to improve quality of life.
Selecting treatment candidates
As chronic HCV infection is a progressive disease that does
not remit spontaneously and may carry substantial bur-
den to the individual, one starting point is that all
infected patients may eventually be candidates for cure,
but everyone does not require treatment immediately.
Thus, questions of when and how treatment should be
applied remain open,especially given the rapidly evolving
therapeutic landscape.
The decision to initiate treatment for chronic HCV infec-
tion remains complex and is ultimately individualized to
the patient situation. Diseaseseverity is the primary factor,
as the prognosis for those with mild to moderate liver
damage is much better than those with cirrhosis. There-
fore, virtually all treatment candidates with chronic HCV
infection should receive some assessment of fibrosis.
Patients with evidence of milder disease (stage 1 out of 4,
METAVIR staging) can safely await future therapy.
Unfortunately, compared with those with mild disease,
those with advanced liver disease (defined as stage 3 or
4 out of 4, and therefore in greater need of a cure) are less
likely to respond, suffer more frequently from certain side
effectsandareatriskofdecompensationwhileontherapy.
Nonetheless, due to the risk of life-threatening events
associatedwithnotachievinganSVR,thosewithadvanced
liver disease should be strongly considered for treatment,
after appropriate risk stratification for those with con-
firmed cirrhosis (i.e endoscopy, screening for hepatoma,
consideration of transplantation referral). Extreme cau-
tion should be exercised for those with evidence of mild
decompensation;treatmentbyexperiencedcentersishighly
advised after determining candidacy for liver transplan-
tation.Forthosewithmoderatedisease(stage2outof4),an
individualized decision should be made, with deferral
possible or even preferable given the novel therapies on
the horizon. An algorithm detailing the decision to treat
based on the primary factor of liver fibrosis is presented in
Figure 1, again re-emphasizing that the decision-making
process should occur on a case-by-case basis.
The provider should screen for advanced fibrosis/cirrhosis
via physical examination, basic laboratory tests (examin-
ing platelet counts, the AST/ALT ratio, prothrombin time,
albumin) and screening by ultrasound [18]. Results from
the above evaluation may increase the likelihood of
cirrhosis if abnormal but lack sensitivity. Given the
importance of the liver fibrosis stage in these treatment
decisions, a more formal fibrosis assessment can be
considered rather than an assessment determined by
history, physical and basic laboratory values/imaging. For
genotype 1 infection, there remains controversy regarding
whether all patients should undergo liver biopsy, the most
accurate assessment of fibrosis, or whether some can be
assessedandmonitoredusingnoninvasivetesting.Astaged
approach utilizes noninvasive testing first: F0-1 and F4
may skip the more invasive liver biopsy as these tests
perform wellat theseendsofthe spectrum.For F2-3,many
would proceed with liver biopsy due to the imprecision
of results in this range, which may either underestimate
or overestimate fibrosis. The details of these noninvasive
approaches are reviewed elsewhere [19,20].
The need for treatment must be weighed carefully against
the likelihood of success and the potential risks and
toxicitiesassociatedwiththerapy.Theprovidermustscreen
for baseline conditions that may be exacerbated by
Table 1. Antiviral medications for genotype 1 infection
PegIFN RBV Protease inhibitor
PegIFN alfa-2a 180 mg per week
Or
PegIFN alfa-2b 1.5 mg/kg per week
RBV (in two divided doses) with food:
<75 kg: 1,000 mg per day
or ≥ 75 kg: 1,200 mg per day;
alternative weight-based dosing:
<65 kg: 800 mg per day
65-85 kg: 1,000 mg per day
>85-105 kg: 1,200 mg per day,
>105 kg: 1,400 mg per day
TVR 750 mg (two 375 mg tablets) orally every 8 h with
food (20 g fat)
Or
BOC 800 mg (four 200 mg capsules) orally every 8 h
with food.
Abbreviations: BOC, boceprevir; PegIFN, Pegylated interferon; RBV, ribavirin; TVR, telaprevir
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therapy. Absolute contraindications are listed in Table 2
[4]. Another limitation is the paucity of data regarding
triple therapies for certain subgroups, such as those with
HIVco-infection,renaldisease,solid-organtransplantation,
and active injection drug users (Table 3). A detailed dis-
cussion of each of these special populations with HCV is
beyondthescopeofthisreportbutitisadvisabletoseekthe
guidance of providers with experience of treating these
“special” populations.
This decision is also influenced by the likelihood of a
response to the above therapies. A higher likelihood of
SVR is associated with factors that are easily modifiable,
Figure 1. Algorithm for the initial evaluation of the patient with genotype 1 HCV infection who is treatment-naïve
Principles that govern this decision tree include the importance of assessing fibrosis stage, the consideration of prognostic testing (such as quantitative
viral load, IL28b), and provision of appropriate care to prevent fibrosis progression and related complications. Abbreviations: AASLD, American
Association for the Study of Liver Diseases; IL28b, interleukin-28 beta subunit; DAA, direct-acting antiviral; HCC, hepatocellular carcinoma; EGD,
esophagogastroduodenoscopy.
Table 2.
Current contraindications to therapies including interferon/
ribavirin
Adapted from AASLD Practice Guidelines[4]
Major uncontrolled depressive illness
Solid organ transplant (renal, liver, lung)
Autoimmune hepatitis or other autoimmune condition known to be
exacerbated by interferon
Untreated thyroid disease
Pregnant or unwilling to comply with adequate contraception (due to
ribavirin’s teratogenicity)
Severe concurrent medical disease
Age less than 2 years
Known hypersensitivity to drug used to treat HCV
Table 3.
Populations in which more data are needed regarding triple
therapies
Decompensated cirrhosis
HIV co-infection
Renal insufficiency/dialysis
Infants and children
Liver transplant recipients
Active injection drug use/substance abuse
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the subtype of virus (1b responding better to protease
inhibitor-based therapy than 1a), and host single nucleo-
tide polymorphisms related to the interleukin-28-beta
subunit (IL28b) [21,22]. Host IL28b genotyping for
rs12979860iscommerciallyavailableintheUnitedStates
and may be additionally useful in predicting whether
patients might be eligible for PegIFN/ribavirin without
protease inhibitor, and for shortened duration of treat-
ment based on early response kinetics [23,24]. Specifi-
cally, those with a favorable host genotype (homozygous
for the C-allele at rs12979860, or CC) have the best
response to interferon-based therapies and, therefore,
treatment should be more favourable. These factors are
probably most useful in decision-making for those with
moderate fibrosis.
Deferral of therapy
If the provider and patient decide to await emerging novel
therapiesduetolowlevelsoffibrosisand/orconcernabout
toxicities, they should work together in the meantime to
minimize disease progression (i.e. avoiding other hepatic
insults such as alcohol or steatosis due to weight gain, and
preventing co-infections such as HIV). If available, enrol-
ment into clinical trials should be discussed.
Preparing the patient for antiviral treatment
TripletherapyregimensareschematizedinFigures2and3.
There are no head-to-head trials to inform the choice of
which protease inhibitor to add for chronic genotype 1
infection[5].Thechoicemay,however,beguidedbyfactors
such as specific side effects, duration of protease inhibitor
therapy,orformularyissues.Ofnoteisthatuseofalead-in
therapy period of 4 weeks prior to protease inhibitor
addition is recommended for boceprevir [25]. Also, for
telaprevir, a similar lead-in period does not compromise
sustained virologic response or add toxicity according
to one trial of prior nonresponders [26]. Therefore, for
selected individuals at high risk of additive toxicities,
one might elect to use a lead-in period even if using triple
therapy with telaprevir. Also, selected patients with
favourable characteristics for interferon-responsiveness
(IL-28b C-C genotype,low viralload)could beconsidered
for initial dual therapy without protease inhibitor [10,27];
if a rapid virologic response (undetectable HCV RNA at
week 4) is not achieved in this subgroup then either
protease inhibitor could be added.
A partial checklist regarding key elements of a pre-
treatment evaluation is shown in Table 4. Known medical
conditions should be optimized (such as control of
diabetes, hypertension, or thyroid disease) and others
anticipated (such as unmasking of cardiac angina due
to onset of anemia). Some patients with risk factors may
require cardiac risk stratification. Baseline anemia should
be worked up and, if feasible, reversed prior to antiviral
treatment. It is also highly advised to assess depression to
screen for modifiable mood disorder, consider potential
referral and establish a baseline for monitoring while on
interferon.
Figure 2. Guide for using triple therapy with boceprevir and response-guided therapy
The regimen consists of a lead-in period of PegIFN/RBV for 4 weeks followed by either 24, 32 or 44 more weeks of triple therapy with boceprevir
(BOC). The shorter course can be used if HCV RNA is undetectable at weeks 8 and week 24. Stopping rules are also shown: if HCV RNA > 100 IU/ml
at wk 12 or HCV RNA detectable at wk 24, therapy should be discontinued.
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models and is labeled as category X by the U.S. Food and
Drug Administration, a female should not become preg-
nant and a male should not impregnate while on this
medication. Use of two forms of contraception is current
standard of care during therapy and for six months
afterwards.
Itiscriticaltoanticipatedrug-druginteractionsandadditive
toxicities while on triple therapy for genotype 1 infection.
Both boceprevir and telaprevir are potent inhibitors of
the cytochrome P450 pathway (specifically CYP3A4),
whichmetabolizesawholehostofprescribedmedications.
It is, therefore, prudent for the provider to carefully and
regularly reconcile a medication list and, if complicated,
enlist the advice of a clinical pharmacist to anticipate
changes in drug levels that might be significant. Herbal
supplements and alternative medications should also be
reviewed. Newly emerging data regarding safe use with
commonly encountered medications and online resources
(such as http://www.hep-druginteractions.org) should
be examined. For instance, in HIV co-infected patients,
treatment of genotype 1 with protease inhibitors has been
tested with only a fairly limited subset of antiretroviral
regimens [28]. The patient should also be instructed to
inform providers of any medication recommended while
on therapy for HCV.
Logisticalissuesshouldalsobeexploredpriortotreatment,
as successful treatment may be limited by insufficient
insurance coverage, transportation to monitoring visits,
pooraccesstoadditionalspecialists,andcultural/language
barriers.Thepatientmayneedtoplanformissedtimefrom
work or family duties, and support systems should be
maximized.Thosewithcirrhosisshouldbeinformedofthe
risk ofdecompensationon interferon-based therapiesthat
necessitates the interruption of treatment.
Table 4.
Sample checklist of items before starting patient on triple
therapies
Obtain baseline HCV RNA (within 6 months of planned start date)
Obtain baseline laboratory tests (i.e. complete blood count plus
differential, renal function, liver function tests, metabolic panel, thyroid
stimulating hormone, prothrombin time)
Consider additional prognostic testing (i.e. IL-28b genotype)
Screen for other infectious diseases that share transmission routes (HIV
antibody, HBsAg)
Screen for other liver diseases (i.e. autoimmune hepatitis, iron overload)
Psychiatric history, screen for active depression and, if necessary, refer
Catalogue and treat comorbid conditions (i.e. substance abuse, anemia,
thyroid abnormalities)
Cardiac risk-stratification for those with multiple cardiac risk factors
Obtain baseline ophthalmologic examination (for those with hypertension,
diabetes)
Ensure adequate contraception for women of child-bearing age and for
sexually-active men
Counsel regarding avoidance of alcohol while on treatment
Counsel regarding common and serious side effects
Keep up-to-date medication lists and screen for drug-drug interactions
Plan for interruption of work or other duties
Plan laboratory monitoring schedule, transportation, communication, and
other logistics
Figure 3. Guide for using triple therapy with telaprevir and response-guided therapy
The regimen consists of a 12 weeks of PegIFN/RBV/TVR for 12 weeks followed by either 12 or 36 more weeks of dual therapy. The shorter course can
be used if HCV RNA is undetectable at weeks 4 and week 12. Stopping rules are also shown: if HCV RNA > 1000 IU/ml at wks 4 or week 12 or HCV
RNA detectable at wk 24, therapy should be discontinued.
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Response-guided therapy describes the adjustment or
cessation of the treatment course based on viral kinetics
afterinitiation(Figures2and3).Response-guidedtherapy
criteria are shown in Figures 2 and 3. For those without
advanced fibrosis/cirrhosis, it is possible that if certain
benchmarks are met, the course may be significantly
shortened. In the case of PegIFN/ribavirin/telaprevir, HCV
RNA at weeks 4 and 12 should both be undetectable
(defining an extended rapid virologic response) to allow a
shortened total course of 24 weeks [29]. For PegIFN/
ribavirin/boceprevir,the testing is doneatweeks 8 and 24;
if both timepoints are completely negative for virus, then
the total course can be shortened to 28 weeks [25].
Animportantfeatureofapplyingresponse-guided therapy
for shortening treatment is the use and interpretation of
sensitiveassays.Recommendedassaysshouldhavealower
limit of quantification of 25 IU/mL of HCV RNA and a
lower limit of detection of around 10-15 IU/mL. These
assays may, therefore, report levels <25 IU/mL, which can
be detected but are unquantifiable. Response-guided
therapy that results in shortened therapy should be based
on results of “undetectable” or “target not detected” [30].
In 2013, based on the algorithm presented in Figure 1,
those with advanced fibrosis/cirrhosis are most likely to be
treated with current regimens. Those with cirrhosis are at
a particularly high risk of lower response rates if therapies
areshortened;thus,currently,thefulldurationof48weeks
is recommended (Figures 2 and 3).
The other principle of response-guided therapy is the
cessation of therapy based on viral measurements reveal-
ing insufficient response and ultimately futility of further
treatment. These “stopping rules” are also described in
Figures 2 and 3. For PegIFN/ribavirin/boceprevir, if HCV
RNA is greater than 100 IU/mL at week 12 or detectable at
week 24, then all three medications should be stopped.
ForPegIFN/ribavirin/telaprevir,ifHCVRNAisgreaterthan
1000 IU/mL at week 4 or 12 or is detectable at week 24,
then medication should be stopped.
Optimal management of side effects
Since therapy is prolonged (24-48 weeks), the provider
should aim to actively diagnose and manage side effects
to minimize their impact on the patient. There are many
potential side effects to therapy; common complications
that require active management are reviewed here.
Cytopenias
Anemia
All three medications used in either regimen can cause
anemia, which occurs at rates of approximately 40% in
phase III trials of telaprevir-containing regimens, and
~50% of those of boceprevir-containing regimens. Given
the high-prevalence of this side effect, several manage-
ment strategies have been used including dose reduc-
tion (particularly of ribavirin), erythropoietic agents, and
transfusion.
Multiple trials of telaprevir-containing regimens excluded
the use of erythrocyte-stimulating agents and managed
anemia with ribavirin dose reduction as the first-line
manuever [31]. For many trials of boceprevir, erythrocyte-
stimulating agents were typically used at the discretion of
the providers; however, a recent randomized controlled
trial comparing erythrocyte-stimulating agents versus
ribavirin dose reduction in the context of PegIFN/
ribavirin/boceprevir treatment showed no difference in
SVR between the two groups [32]. Given the excellent
response rates of these trials and the lower cost and fewer
side effects, ribavirin dose reduction should, therefore, be
the first-line management. For those with rapid onset
significant anemia (generally those with cirrhosis), reduc-
tion of the daily dose by more than 200 mg increments
fromstartingdoseto~600mg/dayisprudent.Ifsignificant
anemia persists despite ribavirin dose reduction, strategies
include addition of erythrocyte-stimulating agent, blood
transfusion,orPegIFNdosereduction.Thedoseofprotease
inhibitorshould never be reduced [25,29,32]. A minimum
haemoglobin level <10 mg/dL is a precipitant for
considering action, but the goal haemoglobin level may
be individualized to the patient based on symptoms and
comorbidities.
Neutropenia
Neutropenia is common during therapy and is most often
attributed to PegIFN. Thus far, despite drops of absolute
neutrophil counts below 500 cells/mL, trials have not
detected an associated increased risk of infection [33,34].
Nonetheless, it is standard to counsel patients with
neutropenia on taking precautions to prevent infection
and to maintain absolute neutrophil counts with com-
bined use of filgrastim and PegIFN dose reduction.
Thresholds for such interventions differ based on indivi-
dualprovidersandguidelines[11,35];oneoptionistoreact
to intervene when absolute neutrophil counts drop below
750 cells/mL for those with known cirrhosis (who are at
generally higher risk of bacterial complications) and when
absolute neutrophil counts drop below 500 cells/mLf o r
those without cirrhosis [35]. If absolute neutrophil counts
cannot be maintained above 500 cells/mLt h e nP e g I F N
discontinuation should be considered.
Thrombocytopenia
Many patients with advanced liver disease start with
abnormally low platelet counts that then drop further due
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during the first weeks after initiation of treatment [36].
Some authorities suggest discontinuation of therapy if
platelet counts are lower than 20,000/mL, and for those
with counts between 20,000 and 50,000/mLP e g I F Nd o s e
reduction should be considered [35]. Recently, the Food
and Drug Administration approved elthrombopag,
a platelet growth factor, as an adjunctive therapy to boost
platelet counts, thus allowing HCV initiation or main-
tenance of therapy [37,38]. Downsides of this therapy
include its cost and its association with potentially
dangerous complications (hepatotoxicity and throm-
boembolic complications, the latter including the portal
vein). The provider should select patients carefully for
elthrombopeg and discuss the risks and benefits fully.
Dermatologic issues
Telaprevir, in particular, is associated with rashes, but it is
important to remember that both PegIFN and ribavirin
may cause dermatologic reactions. PegIFN may result
in both local reactions, generalized dermatitis, and, in
particular,worsenedpsoriasis.Rashesduetoribavirinmay
occur any time during therapy but usually during the
first few months. This overlaps with the timeframe when
telaprevirisadministered,sometimesmakingitdifficultto
determine the offending agent.
Mild to moderate rashes associated with telaprevir are
common. Up to 56% of patients treated with PegIFN/
ribavirin/telaprevirmaysufferfromrashes,comparedwith
about one-third of patients receiving PegIFN/ribavirin
alone [29]. The majority of these eruptions are pruritic,
resemble eczema and are classified as mild to moderate,
often starting in the first 4 weeks of treatment. Severe
rashes were reported in up to 5% of patients, and may
progress to life-threatening exanthems such as drug rash
with eosinophilia and systemic symptoms (DRESS) or
Stevens-Johnson Syndrome (SJS), resulting in a warning
by the Food and Drug Administration to providers [39].
Thus, patients on telaprevir-based therapy must be
instructed to quickly report any skin eruptions to the
provider (who can also monitor), and the rash should
be carefully graded in severity and extent. Mild to
moderaterashes aremanaged withantihistamines,topical
steroids and skin care. Systemic steroids may interact with
telaprevir and are thus not recommended [29]. Rashes
may take several weeks to resolve. Criteria requiring
cessation of telaprevir includes rashes affecting more than
50% ofbodysurfacearea, lesions indicative ofSJS,or with
worsening systemic symptoms. Substitution of boceprevir
for telaprevir successfully resolved rashes in a case report
[40], but more data are needed to assess this strategy.
If cessation of telaprevir occurs after 8 weeks but before
12 weeks, significant benefit is still likely, as indicated by
a trial that included an arm of 8 weeks treatment (69%
cured with 8 weeks PegIFN/ribavirin/telaprevir versus
44% PegIFN/ribavirin alone) [41]. A diagnosis of DRESS
or SJS requires prompt referral for urgent hospitalization,
dermatologic consultation, and cessation of all antiviral
medications [29].
Anorectal complications
Anorectal side effects including discomfort, pruritus, and
hemorrhoids are commonly reported, particularly with
regimens including telaprevir. Insufficient absorption of
telaprevir may be one contributor, so ensuring adequate
fat intake with each dose and avoiding medications that
may interfere with absorption is critical. Over-the-counter
ointments including hydrocortisone or zinc oxide may
provide relief, in addition to keeping the area clean and
dry. For more severe cases, prescription ointments may be
utilized. Both internal and external hemorrhoids may also
become symptomatic, with pain, itchiness, or bleeding.
Patients should avoid constipation and straining while
defecating,aswellasmaintainingwaterintake;laxativesor
stool softeners may also be useful. Rarely, surgical referral
is warranted for severe cases.
Psychiatric complications
Depression is the most commonly encountered psychia-
tric condition found in HCV patients, and may be
exacerbated in about 20% of patients undergoing therapy.
As mentioned, active depression at baseline should
be treated prior to initiation of HCV therapy. Placebo-
controlled trials of pre-emptive antidepressant therapy
for all patients undergoing interferon-based treatment
for HCV have shown variable results, but recent trials of
escitalopram have shown some efficacy [42-44]. For those
with prior history of depression, one should reconsider
institution of an agent that has elicited a clinical response
in the past. For those already stable on antidepressants,
dose adjustments may need to be considered. Repeated
application of validated questionnaire-based instruments
such as the Beck Depression Inventory or the Patient
Health Questionnaire may reveal changes in mood while
on therapy. While providers of interferon-based the-
rapies should be familiar with basic management of
depression, psychiatric expertise is helpful for more
complicated cases.
Conclusion
Since 2011, the addition of direct-acting antivirals boce-
previr and telaprevir to the previous standard of care
providesgreathopeforthecuringofmostgenotype1HCV
infections. Consequently, the goal of preventing liver-
related complications, substantial morbidity and reduced
life expectancy maybemore easily achieved inthe future.
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more complicated; thus, clear and concise guidelines and
principles governing these regimens will help guide the
practitioner navigate this first era of direct-acting antivirals
against HCV. The decision to treat will be made in the
context of future regimens in development that promise
higher cure rates with fewer side effects.
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